Design Therapeutics, Inc.
DSGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.27 | -0.51 | -0.19 | -0.18 |
| FCF Yield | -12.44% | -39.64% | -9.14% | -3.14% |
| EV / EBITDA | -6.71 | -1.96 | -8.73 | -19.29 |
| Quality | ||||
| ROIC | -25.44% | -27.78% | -20.38% | -9.25% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.87 | 0.88 | 0.81 | 0.83 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 26.13% | -12.60% | -68.96% | -253.52% |
| Safety | ||||
| Net Debt / EBITDA | 0.41 | 0.27 | 0.36 | 8.26 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.10 |
| Cash Conversion Cycle | -1,338.74 | -1,318.62 | -2,369.37 | -1,035.58 |